
News|Articles|March 23, 2024
Slideshow: Examining Preferences and Attitudes Around OTC Naloxone
Author(s)Lauren Biscaldi, MS
The first nonprescription, OTC naloxone nasal spray (Narcan) was approved by the FDA in March 2023.
Advertisement
As
References
1. Rodríguez A, Carter C, Glven A, Contreras AU, Hohmann L. A national cross-sectional survey of consumers’ comfort and purchase intentions regarding over-the-counter (OTC) naloxone. Presented at: American Pharmacists Association 2024 Annual Meeting and Exposition; March 22-25, 2024; Orlando, FL. Poster 1315.
2. AlMahasis S, Maurer MM. Development and implementation of best practice alert (BPA) for naloxone prescribing at rural community pharmacies in Wisconsin: a pilot study. Presented at: American Pharmacists Association 2024 Annual Meeting and Exposition; March 22-25, 2024; Orlando, FL. Poster 1323.
3. Marley GT, Shubel C, Gamble AE, Annis I, et al. Naloxone accessibility by standing order in North Carolina community pharmacies. Presented at: American Pharmacists Association 2024 Annual Meeting and Exposition; March 22-25, 2024; Orlando, FL. Poster 1327.
4. Glven A, Carter C, Rodríguez A, Contreras AU, Hohmann L. US consumers’ perceived barriers, access, and preferences surrounding over the counter (OTC) naloxone: A national cross-sectional survey. Presented at: American Pharmacists Association 2024 Annual Meeting and Exposition; March 22-25, 2024; Orlando, FL. Poster 1329.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
The Prodigious PBM Pivot: How Supply Chain Entities Will Move Forward After CAA 2026
2
Q&A: Pharmacists Can Address ADA Standards Across All Settings
3
Executive Order Calls for Realignment of Childhood Vaccines
4
Embedded Pharmacists Are Vital Yet Underutilized in Diabetes Care
5





























































